QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced that its proprietary CHEMOSAT ® ...
69 weeks (16 months) median hPFS in patients with uveal melanoma. 38 weeks (8.5 months) median hPFS in patients with cholangiocarcinoma. Importance of Repeated Treatments: The investigators’ approach ...
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results